Abstract
<p>Super-bioavailable itraconazole (SBITZ) is a new form of itraconazole which overcomes the pharmacokinetic issues of conventional itraconazole (CITZ). Currently two strengths are approved globally for SBITZ; 50 mg and 65 mg which exhibit greater bioavailability than CITZ and widely prescribed in systemic mycosis and dermatophytosis. Though both the strengths have proven to be bioequivalent with CITZ 100 mg but difference was reported in achieving therapeutic concentration of ITZ in patients. Secondly, skin kinetics study in terms of sebum concentration is lacking for both the strengths.</p>
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have